TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Fujirebio Diagnostics AB
Closing information (x1000 SEK)
Closing information | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
Turnover |
321,181
|
310,881
|
265,132 |
Financial expenses |
4,335
|
84
|
474 |
Earnings before taxes |
167,766
|
177,420
|
139,372 |
EBITDA |
173,284
|
183,880
|
144,735 |
Total assets |
774,677
|
644,594
|
615,270 |
Current assets |
476,219
|
335,504
|
296,982 |
Current liabilities |
121,458
|
49,799
|
63,557 |
Equity capital |
645,010
|
587,142
|
545,028 |
- share capital |
641
![]() |
641
![]() |
641 |
Employees (average) |
89
|
86
|
75 |
Financial ratios
Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
Solvency |
83.3%
|
91.1%
|
88.6% |
Turnover per employee |
3,609
|
3,615
|
3,535 |
Profit as a percentage of turnover |
52.2%
|
57.1%
|
52.6% |
Return on assets (ROA) |
22.2%
|
27.5%
|
22.7% |
Current ratio |
392.1%
|
673.7%
|
467.3% |
Return on equity (ROE) |
26.0%
|
30.2%
|
25.6% |
Change turnover |
10,300
|
45,749
|
14,911 |
Change turnover % |
3%
|
17%
|
6% |
Chg. No. of employees |
3
|
11
|
4 |
Chg. No. of employees % |
3%
|
15%
|
6% |
Total value of public sale
Fiscal year | 2024/03 (consolidated) | 2023/03 (consolidated) | 2022/03 (consolidated) |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.